Short‐term echocardiographic evaluation by global longitudinal strain in patients with heart failure treated with sacubitril/valsartan
Abstract Aims The angiotensin receptor neprilysin inhibitor (ARNI) sacubitril/valsartan reduces mortality and hospitalizations in patients with heart failure and reduced ejection fraction (HFrEF). Favourable effects on haemodynamic and functional parameters have been observed in patients with HFrEF...
Saved in:
Main Authors: | Simone Mazzetti, Chiara Scifo, Raffaele Abete, Davide Margonato, Margherita Chioffi, Jessica Rossi, Matteo Pisani, Giovanni Passafaro, Massimiliano Grillo, Daniele Poggio, Andrea Mortara |
---|---|
Format: | Article |
Language: | English |
Published: |
Wiley
2020-06-01
|
Series: | ESC Heart Failure |
Subjects: | |
Online Access: | https://doi.org/10.1002/ehf2.12656 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Progress in Managing Heart Failure: an in-depth Review of Sacubitril/Valsartan Combination Therapy
by: Neeraj Hiremath, et al.
Published: (2024-04-01) -
Angiotensin-Neprilysin Inhibitor Therapy: A Retrospective Chart Study
by: Roda Plakogiannis, et al.
Published: (2025-02-01) -
Efficacy and Safety of Sacubitril/Valsartan Versus Amlodipine in Japanese Patients With Essential Hypertension: A Randomized, Multicenter, Open‐Label, Noninferiority Study (PARASOL Study)
by: Koichi Yamamoto, et al.
Published: (2025-01-01) -
Angiotensin receptor neprilysin inhibition versus individualized RAAS blockade: design and rationale of the PARALLAX trial
by: Rolf Wachter, et al.
Published: (2020-06-01) -
Clinical determinants and prognostic implications of renin and aldosterone in patients with symptomatic heart failure
by: Masatake Kobayashi, et al.
Published: (2020-06-01)